Introduction

53
Tourette Syndrome (TS) is a chronic neuropsychiatric disorder defined by the presence of both 54 vocal and motor tics that begin early in life, fluctuate in phenomenology over time, and are not 55 caused by another illness (American Psychiatric Association 2000). Tics are brief movements or 56 noises, repeated many times a day in a stereotyped fashion, that may look intentional but that 57 serve no useful purpose (Black 2010b to dopamine stimulation could be located downstream in striatum, pallidum, thalamus, or cortex 81 (Mink 2006 concentration, a second scan was done while the infusion continued. The order (levodopa on day 154 1 and placebo on day 2, or the reverse) was assigned randomly to each subject, and subjects and 155 PET staff were blind to drug assignment during all scans. 156
The room was darkened and subjects were instructed to lie quietly in the scanner with eyes 157 closed throughought each scan. Study staff asked subjects every 5 or 10 minutes if they were 158 comfortable and made sure they were awake. 159
Levodopa infusion 160
Subjects took 200mg carbidopa by mouth at least 1 hour before levodopa infusion began. A dose 161 of levodopa estimated to fill each subject's volume of distribution at a target concentration of 162 600ng/mL was infused over 10 minutes, followed until the second PET scan of the day was 163 completed by a maintenance infusion at a rate estimated to compensate for elimination. In prior 164
work, these infusion rates produced a mean blood level across subjects of ~625ng/mL after 25 165 minutes of infusion and the specific activity exceeded 500 Ci/mmol, as determined by analytical HPLC. The mass of 181 raclopride was <13.9 µg per injected dose. 182
Image acquisition 183 RAC* 14.5 ± 4.79mCi (mean ± S.D.) was given i.v. over an interval of 30 seconds. PET images 184
were acquired on a Siemens ECAT 961 camera beginning with arrival of radiotracer in the head 185 and continuing for 60 minutes using image frames of increasing duration. 186
An MP-RAGE sequence was used to acquire a 3-dimensional T1-weighted image of the brain 187 with acquisition time ~400 sec and voxel dimensions 1.25x1x1mm 3 . 188
Image alignment 189
The PET images were realigned within each subject and then to the subject's MRI using a rigid- to each subject's realigned PET images using the optimized MRI-to-PET transformation matrix 202 computed in the alignment step. The cerebellar VOI was trimmed if needed so that no voxel in 203 the VOI corresponded to any of the inferior-most 4 slices in any frame of that subject's original 204 PET images. Thus in each subject each VOI was identical for all 4 PET scans. 205
The binding potential BP ND (Innis et al. 2007; Mintun et al. 1984) , an estimate of the quotient 206 B max /K D , was computed as one less than the distribution volume ratio (DVR), which was derived 207 for each of the nine subcortical VOIs and the frontal lobe VOI using the cerebellar reference 208 region (Logan et al. 1996 
Whole-brain analysis 219
For each subject, a DVR image was computed using at each voxel in the brain the Logan 220 graphical method with the cerebellar VOI described in the preceding section as reference region 221 (Logan et al. 1996) . As a methods check, the mean across striatal VOIs of the voxelwise DVR 222 value was essentially identical to the regional DVR computed using the standard methods 223 described above. Analysis was limited to voxels in atlas space at which every subject contributed 224 data from all frames of the dynamic PET acquisition. Two comparisons were made, one based on mean baseline DVR images and the other based on 231 levodopa effect ΔDVR images. Each subject's two pre-infusion RAC* PET scans, one from each 232 scan day, were averaged to create that subject's mean baseline DVR image. The difference of the 233 during-levodopa DVR image and the during-placebo DVR image in a subject was used to create 234 that subject's levodopa effect ΔDVR image. 235
Results
236
Subjects 237
Subject characteristics and adequacy of matching are reported in Table 1, and clinical  238 characteristics of the Tourette syndrome group are reported in Table 2 . 239
Levodopa levels 240
Levodopa plasma concentrations were ~800-1000ng/ml before the RAC* scan and ~500-241 700ng/ml after the RAC* scan, and did not differ significantly between groups (Table 3) . 242
Baseline RAC* binding 243 Across VOIs, RAC* binding did not differ significantly between tic and control subjects 244 (multivariate main effect of diagnosis, F=0.744, df=1,8, p=0.413; tic vs control). Nevertheless, 245 baseline RAC* binding was numerically higher in TS by 13-17% in the three striatal VOIs and 246
by 5-7% in the FL and Th VOIs. The whole-brain analysis identified no significant differences in 247 baseline RAC* binding between TS and control subjects. 248
Stability of RAC* binding between days and with time 249
This study includes a before-and after-infusion scan on each of two days. On one day the 250 infusion contains levodopa, and on the other day the solution is a saline placebo. Thus each 251 subject has three non-levodopa scans (the first scan of each day plus the scan during the placebo 252 infusion). As expected, BP ND was similar in the two pre-levodopa scans (correlated at r = 0.99 253 across VOI and subject). 254 BP ND increased between the 1 st and 2 nd scan of the day ( Fig. 4; There was a trend for the change in BP ND during the infusion to be smaller in tic subjects ( 
Effect of levodopa on RAC* binding 267
Since the pre-and on-placebo scans differed, the only appropriate comparison for the on-268 levodopa *RAC scan is the on-placebo scan. Therefore we assessed the effect of levodopa by 269 comparing the BP ND in the post-LD and post-placebo scans. 270
In the VOI analysis, there was no significant effect of LD (day x time interaction, F=0.014, 271 df=1,8, p=0.909), the effect of LD did not differ overall in tic subjects (day x time x diagnosis 272 interaction, F=1.308, df=1,8, p=0.286), and the 4-way interaction (diagnosis x day x time x 273 region) was not significant (F=1.577, df=5,4, p=0.340). However, the diagnosis x day x time 274 interaction was significant for pallidum (p=0.050) with a trend in thalamus (p=0.098; Fig. 6 ). In 275 these regions BP ND decreased in control subjects, consistent with increased dopamine release 276 during the levodopa infusion, whereas the mean effect in the tic subjects was in the opposite 277 direction. 278
The whole-brain analysis identified a similar effect (decreased RAC* binding with levodopa in 279 controls, increased in TS) in a cluster of 38 midbrain voxels (1.0 ml) with peak t at atlas 280 coordinate (1.5, −21, −15) and extending laterally, in the right substantia nigra (peak t(_df) = 9.0, 281 FDR corrected p=0.002; Fig. 7A ). A second significant cluster of 19 voxels (0.5 ml) was seen in 282 parahippocampal gyrus (peak t=7.92 at (22.5,−39,−6), corrected p=0.023; Fig. 7B ). The mean 283 regional change in BP ND with levodopa is shown in Fig. 7C . Note that in both these clusters, the 284 BP ND on placebo was positive in all subjects (p < 0.001, binomial distribution), consistent with 285 nontrivial RAC* binding. The highest t value in the whole-brain comparison, 11.62, occurred at 286 (−31.5, 6, −15) in Brodmann's area 13 (uncorrected p = 1.37 × 10 −6 ; Bonferroni threshold 1.17 × 287 10 −6 ), but the cluster volume was only 0.1 ml, not significant by FDR correction (Fig. 7D) . A 288 third statistically significant cluster was centered at the posterior edge of the occipital lobe; both 289 the location and the observation that in this cluster the BP ND on placebo was negative in half the 290 subjects suggests that this cluster likely does not reflect D2R binding. 291 twice each on the same day using a bolus-plus-constant-infusion method, and found no 310 significant mean change from the first to the second scan. However, Alakurtti and colleagues 311 (2011) found that mean BP ND increased from the first to the second scan of the day in striatal and 312 thalamic regions, with the change (about +5%) reaching statistical significance in medial and 313 lateral thalamus. 314
Discussion
The observation in the present study that BP ND increased from the first to second scan of the day 315 is consistent with this background, and has implications for RAC* challenge PET studies in 316 general, because essentially all such studies use a before-vs. after-intervention design. Our 317 results and those of Alakurtti et al. (2011) suggest that the before-after design is flawed in that 318 BP ND increases from the first to the second scan even without active intervention. This does not 319 invalidate the results of methylphenidate challenge RAC* studies, since that challenge decreases 320 striatal RAC* BP ND by a large fraction, but it may mean that before-after RAC* studies are less 321 sensitive to manipulations that would decrease dopamine release. 322
Possible pathophysiological interpretation 323
The increase in BP ND during the placebo infusion is most likely associated with passage of time 324 rather than a placebo effect per se, especially as placebo administration is more likely to increase 325 dopamine release (de la Fuente-Fernandez et al. stimulate phasic dopamine release, but under endogenous control. Recall that the concern with 362 stimulants as challenge agents was that they cause a substantial release of dopamine at the 363 striatal synapse regardless of current environmental demands; it may produce a ceiling effect for 364 dopamine release that does not reflect typical endogenous control. A sensible hypothesis to 365 explain the results of the present study would be that a research subject lying awake in a quiet, 366 darkened room without specific cognitive demands has no need for substantial phasic release of 367 dopamine, and thus even if exogenous levodopa has added dopamine to presynaptic vesicles, 368 they are not released at a substantial rate at the synapse. A levodopa-raclopride study of a motor 369 task in healthy individuals provides direct experimental support of this hypothesis (Flöel et al.  370 2008). That study was properly designed with two sessions, placebo on one day and levodopa on 371 another, with randomized order. Levodopa increased striatal dopamine release during 372 performance of a motor task, but not at rest! Since in the present study all subjects were at rest 373 during all scans, the results are consistent with those of Flöel and colleagues (2008) . 374
Levodopa effect on RAC* binding in midbrain, cortex, and thalamus 375
Levodopa stimulated dopamine release in controls but reduced it in TS subjects in midbrain 376
(approximately VTA/substantia nigra) and in parahippocampal gyrus. Similar effects, though not 377 statistically significant, were observed in orbital cortex (Brodmann's area 13) and in thalamus. 378
One expects exogenous levodopa to increase dopamine release in the substantia nigra, and this 379 occurred in the control subjects. D 2 and D 3 dopamine receptors are present in the substantia nigra 380 and their activation inhibits spike firing, dopamine synthesis and dopamine release by nigral 381 dopaminergic cells (Grace 2002) . We hypothesize that levodopa increased dopamine stimulation 382 of these inhibitory D2-like receptors in control subjects, and this may have prevented levodopa 383 from stimulating nigrostriatal dopamine release into the striatum. Explaining the similar difference in nigral levodopa response in TS in parahippocampal gyrus 394 and orbital cortex is no easier. Nevertheless, these results document an abnormality of 395 presynaptic dopaminergic pharmacology in TS. 396
There was a trend for a similar effect in thalamus; dopamine release increased with levodopa 397 infusion in control thalamus but decreased in TS subjects. A [ 11 C]FLB-457 PET study found a 398 similar result, in that amphetamine provoked thalamic dopamine release in control subjects but 399 not in TS (Steeves et al. 2010 concentration of D2-like receptors is low in cortex compared to striatum, the counting statistics 406 are poor for cortical VOIs of similar volume, and this renders the computed BP ND s suspect. For 407 instance, some regional RAC* BP ND s are negative or close enough to zero that displacement 408 studies produce results that are hard to interpret. In the present study, FreeSurfer-defined cortical 409 regions allowed the creation of a large, reliably defined frontal lobe VOI, in which PET time-410 activity curves were low in noise (Fig. 3B) , allowing statistically reliable estimates of BP ND that 411 were uniformly positive. Similarly RAC* displacement in thalamus has previously shown 412 adequate counting statistics and reliability (Alakurtti et al. 2011; Hirvonen et al. 2003) . 413
The second concern with RAC* in extrastriatal regions is one of validity or interpretation. 414 RAC* binding in cortex occurs at low levels, only some of which is attributable to specific 415 binding (Farde et al. 1988 ). The concern is whether specific binding in cortex represents 416 dopamine D2-like receptors. D2 and D4 receptors are expressed in human prefrontal cortex, 417 though at relatively low concentrations compared to striatum ( Finally, the limited sample size for the comparison of the TS and control groups likely prevented 424 identifying some true differences (type II error). Nevertheless, the sample size was adequate to 425 find the significant group differences described above. 426
Future directions 427
These results suggest a natural next step for research in TS: testing whether dopamine release in 428 TS differs during a dopamine-releasing cognitive (or other) task. Levodopa may augment the 429 task-evoked release or interact with it differently in people with versus without tics. Along these 430 lines, a cognitive-pharmacological interaction fMRI study found that LD changed the BOLD 431 responses to a working memory task (Hershey et al. 2004) . A newer levodopa infusion produces 432 roughly twice as high a levodopa plasma concentration as the infusion used in this study (Gordon 433 et al. 2007) , and may produce greater dopamine release. 434 
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